PublizoomAward notice Supplies
Purchase, storage and delivery of live attenuated homologous vaccine against Lumpy Skin Disease
- Public buyer
- European Commission, DG SANTE - Health and Food Safety
Brussels - Place of performance
- 1040 Brussels
not published: buyer's address - Estimated value
- €3,200,000 excl. VAT
- Amount awarded
- €2,385,950 excl. VAT
- Planned end of contract
- 15 September 2030
likely re-tender around March 2030 - Bids received
- 5
- Procedure
- Open procedure
Any company may submit a bid. - Publication
- 1 October 2026
- Notice language
- English
AI analysis: go for it or not?
Summary in English, criteria, documents to provide and a GO / NO GO verdict in one minute.
Unlimited analyses during the 14-day Pro trial, no card needed.
Description
REASON FOR PURCHASING The Commission has to maintain an estimated stock of at least 528.000 doses of live attenuated Lumpy Skin Disease (LSD) vaccine in storage in order to make it rapidly available in case it is needed. In addition, this stock of 528.000 doses of live attenuated vaccine should be replaced quickly, within 4 weeks, when depleted, in order to maintain the Union’s capability to respond to an emergency. PROCUREMENT DESCRIPTION The purpose of the contract is:
- The purchase of an estimated maximum 2.640.000 doses of live attenuated homologous vaccine against LSD. This will be executed with one initial purchase of 528.000 and up to four (4) replenishments, of 528.000 doses each, upon request from the Commission.
- The storage of an initial stock of 528.000 doses, readily available for delivery to any of the destinations listed in the technical specifications, that can be replaced, if depleted, partially or totally, up to 4 times until the end of the contract, upon request from the Commission.
- The timely delivery of maximum 2.640.000 doses divided in as many consignments as needed to any of the destinations listed in the technical specifications
- The storage of any vaccines in stock at the end of the contract for the remainder of their shelf life
- The proper destruction and disposal of any unused vaccine at the end of its self life.
Awarded to
CPV codes
European codes that classify what the contract is about. They are how we find the tenders for your trade.
33651690
Winning prices for comparable contracts
- A quarter below
- €290,000
- Median
- €403,000
- A quarter above
- €1,351,075
Amounts awarded (excl. VAT) over the last 3 years for 5 contracts in the same CPV group (3365…), excluding framework agreements. Half of the contracts fall between the two quartiles. TED source: mostly contracts above the EU thresholds, so amounts tend to be high.
Similar contracts already awarded
| Contract | Winner | Amount |
|---|---|---|
| Purchase, storage and delivery of live attenuated vaccine against Sheep Pox European Commission, DG SANTE - Health and Food Safety · 12 January 2026 |
VETAL Hayvan Sagligi Urunleri A.S. | €403,000 |
| Purchase, storage and delivery of live attenuated vaccine against Peste des Petits Ruminants European Commission, DG SANTE - Health and Food Safety · 15 January 2025 |
Jordan Bio-Industries Center-JOVAC | €290,000 |
| Immunoglobuline humaine normale pour administration intraveineuse Cliniques universitaires Saint Luc · 22 October 2026 |
CSL BEHRING | €16,277,080 |
| Antimycotica AZ Delta vzw · 21 October 2026 |
Arega Pharma NV Sandoz NV Fresenius Kabi NV Pfizer NV |
€300,945 |
| Raamovereenkomst voor het leveren van immunoglobulines IV 10% Universitair Ziekenhuis Gent · 24 September 2026 |
CSL BEHRING NV | €27,360,000 |
Source : TED – Office des publications de l'Union européenne © Union européenne, données retraitées. Reference 675871-2026.